Browsing Tag
Eli Lilly and Company
171 posts
Novo Nordisk’s $1.4bn Orbis deal pushes obesity drug race deeper into oral medicines
Novo Nordisk has signed a discovery and licensing agreement worth up to $1.4 billion with Orbis Medicines to develop orally available macrocycle therapies for cardiometabolic disease, extending the Wegovy maker’s strategy beyond injectable GLP-1 drugs and its existing oral semaglutide technology.
Superluminal lands $60m Series B to take genetic obesity drug into human trials
Superluminal Medicines has secured an oversubscribed $60 million Series B to move a selective small-molecule MC4R agonist into Phase 1, entering an obesity niche where Rhythm Pharmaceuticals already generates more than $70 million a quarter.
Moonwalk Biosciences secures $70m Series B for adipose-targeted RNAi
Moonwalk Biosciences has secured $70 million to advance MW101 toward human testing, taking disclosed financing since launch to $127 million as the biotech pursues an adipose-targeted alternative to appetite-based obesity therapies.
Elecsys pTau217 wins FDA clearance as Roche pushes Alzheimer’s testing into primary care
Roche has secured FDA clearance for Elecsys pTau217, giving more than 4,500 existing U.S. cobas analyzers a potential role in assessing Alzheimer’s amyloid pathology through a routine blood draw.
Eli Lilly targets autoimmune pipeline with $2.875bn Merida Biosciences acquisition
Eli Lilly is paying up to $2.875 billion for privately held Merida Biosciences only about 17 months after the biotech launched with $121 million. The lead asset remains in Phase 1, making the transaction less a conventional pipeline purchase than a bet that selectively eliminating disease-causing antibodies can open a new class of autoimmune and allergy medicines.
New Alzheimer’s imaging approval could help unlock Lantheus’ neurology merger payouts
TAUKLARIFY wins FDA approval as Lantheus expands its Alzheimer’s imaging franchise ahead of Curium’s $8bn acquisition and neurology CVR targets.
Lilly (NYSE: LLY) now gets 65% of H1 revenue from Mounjaro and Zepbound
Mounjaro and Zepbound generated $27.69 billion for Eli Lilly and Company in H1 2026, or almost 65% of total revenue. Excluding the two tirzepatide brands, revenue grew by only about 11%.
Eli Lilly (NYSE: LLY) raises 2026 guidance as Mounjaro and Zepbound reshape pharma growth
Eli Lilly raises 2026 guidance as Mounjaro and Zepbound drive 48% Q2 revenue growth. Read how LLY’s GLP-1 scale reshapes Big Pharma.
ResMed’s FY27 guidance reset tests investor confidence in sleep-apnea device growth
ResMed’s FY27 guidance reset pressured RMD despite strong cash flow. Read how Astral, GLP-1 drugs, MatrixCare and buybacks shape the medtech story.
OPKO Health (Nasdaq: OPK) raises $125m against mazdutide royalties as GLP-1 financing strategy deepens
OPKO Health raises $125 million against mazdutide royalties. Read how the KKR-linked financing reshapes OPK’s GLP-1 capital strategy.